A case of hepatitis B virus and hepatitis C virus co-infection that achieved sustained virological response 12 following treatment with glecaprevir hydrate/pibrentasvir for 3 days

Numata Yasunao, Sasaki Shigeru, Akutsu Noriyuki, Hirano Takehiro, Wagatsuma Kohei, Kawakami Yujiro, Ishigami Keisuke, Nakase Hiroshi

doi:10.2957/kanzo.62.578

Bibliographic Information

Other Title

グレカプレビル水和物・ピブレンタスビル配合剤の3日間投与で持続的ウイルス学的著効を達成したHBV・HCV共感染の一例
グレカプレビルスイワブツ・ピブレンタスビルハイゴウザイノ 3ニチカントウヨデジゾクテキウイルスガクテキチョコウオタッセイシタ HBV ・ HCV キョウカンゾメノイチレイ

Search this article

Abstract

<p>An 82-year-old female patient who was co-infected with hepatitis B virus (HBV) and hepatitis C virus (HCV) was regularly followed at our institution. The patient was taking clarithromycin because of comorbid nontuberculous mycobacteriosis (NTM) lung disease. Since chronic liver damage has possibly progressed, the patient was treated with direct-acting antiviral (DAA). Soon after taking DAA, severe pruritus appeared, and the patient stopped it in 3 days. However, HCV RNA level decreased to an undetectable level 2 weeks after the start of the treatment and achieved sustained virological response (SVR) 12. Two factors were considered for the success of DAA treatment in a short period in this case. One factor was that the immune response for HCV elimination was easily generated due to the patient's high immunological activity caused by the effects of co-existing NTM lung disease and co-infection with HBV. The other reason is that the blood level of DAA was high because of the concomitant drug.</p>

Journal

Kanzo

Kanzo 62 (9), 578-584, 2021-09-01

The Japan Society of Hepatology

Keywords

Details 詳細情報について

Export